Novavax (NASDAQ:NVAX) has its skeptics. Some point to the company’s history of failure. Its respiratory syncytial virus (RSV) vaccine candidate ResVax experienced two clinical setbacks, and it has …
https://www.fool.com/investing/2021/09/06/this-could-be-novavaxs-ace-in-the-hole/

